With the coronavirus pandemic pausing FTC reviews and complicating supply chains, Mylan is flying a holding pattern on its megamerger with Pfizer’s Upjohn unit and scrambling to deal with worldwide drug demand at the same time.
Looking for a steady hand in trying times, Mylan found just the man for the job—again.
The generics giant is bringing back Robert J. Coury, its current chairman of the board and former CEO, to the role of executive chairman as the drugmaker navigates its way through the final stages of a generics megamerger with Pfizer’s Upjohn unit, the company said Wednesday.
Coury, who stepped away from the CEO role in 2012 in favor of Heather Bresch, previously held the executive chairman’s job from 2012 to 2016.
Coury’s promotion will “formalize and align” his title to the work he’s already been doing as Mylan responds to the novel coronavirus pandemic and pieces together its integration plans for the Upjohn merger, Mylan said. Coury’s new title will carry over to his planned role at the merged company, dubbed Viatris.
In taking on the new title, Coury will keep his base salary of $1.8 million a year, with any additional compensation “determined by the Viatris Board of Directors (should the merger close) or by the Mylan Board if it does not,” according to an SEC filing.
That small caveat reads as particularly ominous after Mylan and Pfizer delayed the Viatris merger past its mid-2020 close date due to “unprecedented circumstances” surrounding the novel coronavirus pandemic.
In March, the drugmakers said they would postpone the close until the second half of 2020, citing “delays in the regulatory review process” associated with COVID-19. At the time, Mylan said it did not expect any changes to the terms of the deal.
Later in the month, hoping to get the regulatory ball rolling, Mylan and Upjohn agreed to concessions as part of the European Commission’s antitrust review of the merger, according to a commission filing. While the EU did not disclose what those concessions were, the sale of competing assets in merging drugmakers’ portfolios is often a prerequisite for antitrust clearance.
If the Viatris merger does pass muster, the new company would refresh Coury’s long run as Mylan’s head––a tenure not without controversy.
In recent years, Coury has stood out among biopharma executives for his outsized pay packages and corporate perks. His exit package, granted as he stepped down from the executive chairman job, amounted to $97 million. And a remarkably lucrative corporate jet arrangement, for instance, still provides him up to 70 hours of flight time or a $1.5 million check. That allowance––nearly three times higher than the second-place finisher, AbbVie CEO Rick Gonzalez––put Coury at the top of FiercePharma’s top “jet-setting” executives list for 2018.
As executive chair at Viatris, Coury would top a senior leadership team flush with Mylan and Pfizer veterans.
Viatris is set to appoint current Pfizer board member W. Don Cornwell as well as eight current Mylan directors: JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry Korman, Rajiv Malik, Richard Mark, Mark Parrish and Pauline van der Meer Mohr. Malik currently serves as Mylan’s president and will keep that role at Viatris, Pfizer said.
Those nine will join Ian Read, Pfizer’s former CEO and executive chairman; Pfizer board member James Kilts; and Michael Goettler, who was named Viatris CEO. Read, Cromwell and Kilts will step down from their roles at Pfizer to move over to the new company, Pfizer said. Additionally, Upjohn CFO Sanjeev Narula will move to Viatris in the same role, bringing 16 years of experience at Pfizer with him.
By Kyle Blankenship
Source: Fierce Pharma
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.